SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending amid community excitement surrounding potential connections to Elon Musk's Grok AI and mentions from notable figures. The 'Byte Army' is rallying, fueled by the coin's zero-tax setup and positioning within the AI-meme coin space, anticipating significant growth.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare ($NET) is trending due to the company's recent unveiling of "NET Dollar", a stablecoin initiative aimed at facilitating AI agent transactions, sparking discussions about its potential impact on the company's growth amid existing debt. The community is actively analyzing the strategic implications and potential risks of this move, especially considering Cloudflare's strong performance and position in the cloud infrastructure sector. Sentiment is also driven by strong technicals and analyst upgrades, indicating confidence in Cloudflare's continued growth and innovation.

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Cigna Group (The)

Cigna Corp.

Cigna ($CI) is trending amid discussions around pharmacy benefit management (PBM) scrutiny and potential regulatory hurdles, particularly following executive comments and competitor earnings. Community members are debating the stock's valuation, buyback programs, and exposure to Medicare/Medicaid, while also weighing potential impacts from broader healthcare policy changes. Some see Cigna as undervalued and strategically positioned, while others express concerns about market headwinds and profitability.

Direxion Shares ETF Trust - Direxion Daily South Korea Bull 3X Shares

Direxion Daily South Korea Bull 3X Shares

KORU is trending as investors monitor the volatile won-dollar exchange rate and potential impacts from upcoming Korea-US summit negotiations, including possible increases in defense spending. The community is weighing potential pullbacks and entry points, with some highlighting the KOSPI index's strong performance this year. Community members are also closely following ongoing political developments in South Korea.

U.S. Bancorp operates as a bank holding company, which offers financial services including lending and depository services, cash management, foreign exchange and trust and investment management. The firm also offers mortgage, refinance, auto, boat and RV loans, credit lines, credit card services, merchant, bank, checking and savings accounts, debit cards, online and mobile banking, ATM processing, mortgage banking, insurance, brokerage and leasing services. The company was founded on April 2, 1929, and is headquartered in Minneapolis, MN.

U.S. Bancorp.

U.S. Bancorp is trending due to observed options activity and analyst target price adjustments, with Citigroup raising its target. Community discussion includes speculation on potential acquisitions and the impact of rate cuts and deregulation. Recent news focuses on dividend hikes and the company's renewed focus on bitcoin custody services, which are also driving investor interest.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is trending due to a mix of factors including unusual options activity indicating potential bearish sentiment, while analysts are weighing its upside potential against Wells Fargo, particularly in light of possible Fed rate cuts. Community discussions also revolve around restructuring efforts, partnerships for cross-border payments, and a strategic stake sale in Banamex, as well as overall valuation in comparison to its peers in the financial sector.

MYX Finance

MYX Finance is experiencing significant volatility, with community members actively discussing recent price surges and pullbacks. Some traders are pointing to potential resistance levels and corrective pullbacks, while others compare it to similar projects backed by major players like Coinbase and Binance. The conversation also includes speculation about future price movements and potential shorting opportunities.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

COP is trending due to options activity and discussions around its resilience amid fluctuating oil prices, with community members weighing bullish and bearish sentiments. Some analysts are adjusting price targets, while others highlight the potential benefits of the Marathon Oil acquisition and LNG deals. Discussions also revolve around the company's dividend policy and potential for long-term profitability in a volatile energy sector.

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Mckesson Corporation

McKesson is trending due to positive sentiment around its fiscal 2026 profit outlook and efficient management. Community members are actively discussing target prices and updated ratings from analysts, with many highlighting the potential for ROI via call options. Some traders view MCK as a defensive play in the healthcare distribution space, citing consistent revenue and cash flow.

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Niagen Bioscience Inc.

Niagen Bioscience ($NAGE) is trending as the community discusses recent gains and upcoming catalysts, with a focus on clinical trial results and their potential impact. Discussions include institutional ownership, short interest, and the company's new patent. Optimism surrounds potential partnerships and broader market recognition of Niagen's value proposition in cellular health and longevity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Third Harmonic Bio, Inc. (THRD) drew investor attention on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.thirdharmonicbio.com/news-releases/news-release-details/third-harmonic-bio-announces-plan-liquidation-and-dissolution">announced </a>that its board of directors has approved a plan for the liquidation and dissolution of the firm and the distribution of remaining cash to stockholders.The company plans to file a certification of dissolution with the Secretary of the State of Delaware in the third quarter of 2025, provided that stockholders authorize the decision at their annual meeting on June 5.The company will subsequently delist its shares of common stock from Nasdaq.Third Harmonic Bio CEO said that after reviewing strategic alternatives, the management team and board of directors determined that returning cash to shareholders and selling its assets is the “best path forward.”The company expects that its existing capital resources, coupled with the anticipated net proceeds from the sale of certain clinical assets, will enable it to meet its remaining liabilities and obligations with sufficient reserves.The company estimates that the initial distribution will be between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock. The amount will be distributed after the company files for dissolution in the third quarter.It added that the estimates do not include any cash that may become available for distribution following sales of the company’s assets.The company said that it will complete all Phase 2 readiness activities for its lead product candidate THB335, aimed at treating chronic spontaneous urticaria, by mid-year to maximize the program's value, which will be sold as part of the dissolution plan.Following the announcement, shares of the company rocketed over 39% in Monday’s pre-market session.On Stocktwits, retail sentiment around Third Harmonic Bio fell from ‘neutral’ to ‘extremely bearish’ over the past 24 hours while message volume rose from ‘extremely low’ to ‘extremely high.’<figure class="image"><img style="aspect-ratio:650/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_7_59_17_AM_png_4ae3a9f87c.webp" alt="THRD's Sentiment Meter and Message Volume as of 8:05 a.m. ET on April 14, 2025 | Source: Stocktwits" width="650" height="149"><figcaption>THRD's Sentiment Meter and Message Volume as of 8:05 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/THRD">THRD stock</a> fell by about 67% year-to-date and by 69% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ends-development-of-weight-loss-pill-danuglipron/chfCPelRba2">Pfizer Ends Development Of Weight Loss Pill Due To Potential Drug-Induced Liver Injury In A Patient</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered

The company plans to file a certification of dissolution with the Secretary of the State of Delaware in the third quarter of 2025, provided that stockholders authorize the decision at its annual meeting of stockholders on June 5.

Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 38% Pre-Market, But Retail’s Shattered

Equity

The volume for Third Harmonic Bio stock increased for one day, resulting in a record-breaking daily growth of 204% of the 65-Day Volume Moving Average

THRD's total volume now sits at 229.4K. The +-0.21% price change was insignificant, leaving IBM's price at $9.44...

Third Harmonic Bio Welcomes New Director, Geoff McDonough

Third Harmonic Bio, Inc. (THRD) has issued an update. Geoff McDonough has been appointed as a Class III director at Third Harmonic Bio, Inc., follo...

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases...

Third Harmonic Bio Inc (THRD) Reports Decreased Net Loss in Q4, Aligns with Analyst Projections

THRD's Fiscal Discipline Leads to Lower Annual Net Loss Despite Zero RevenueRelated Stocks: THRD...

Third Harmonic Bio GAAP EPS of -$2.45 misses by $1.20

Third Harmonic Bio GAAP EPS of -$2.45 misses by $1.20...

Buy Rating for Third Harmonic Bio Amidst Promising Drug Pipeline and Market Potential

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on THRD stock, giving a Buy rating today. Sam Slutsky has given his Buy rat...

TD Cowen Remains a Buy on Third Harmonic Bio, Inc. (THRD)

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Third Harmonic Bio, Inc. (THRD Research Report). The company's...

Recap: Third Harmonic Bio Q4 Earnings

Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN...

Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '25	-$0.27	--	--	N/A
Q4 '24	-$0.36	-$0.35	3.70%	BEAT
Q3 '24	-$0.30	-$0.30	-0.30%	MISSED
Q2 '24	-$0.29	-$0.29	0.42%	BEAT
Q1 '24	-$0.31	-$0.20	35.50%	BEAT

THRD
THIRD HARMONIC BIO INC

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '24

Historical Earnings

Latest THRD News

THRD THIRD HARMONIC BIO INC